Authors

Latest:

Importance of Real-World Data in Supporting Treatment Options

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Sa Wang, MD, MD Anderson Cancer Center

Latest:

Unmet Needs in SM Treatment

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Duncan McLaren, MBBS, BSc, FRCR, FRCP

Latest:

Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP

Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.

John Ligon, MD

Latest:

Dr. Ligon on Delivering CAR T-cell Therapy via Mediport Lines in Pediatric B-Cell Malignancies

John Ligon, MD, discusses findings from a study investigating the use of mediports to deliver CAR T-cell therapy in patients at Pediatric Real-World CAR Consortium medical centers.

Inderjit Mehmi, MD

Latest:

Dr Mehmi on the Rationale for Investigating Fianlimab/Cemiplimab in Advanced Melanoma

Inderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features

Monica Peravali, MD

Latest:

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.

Bradley W. Christensen, MD

Latest:

Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

Christopher Jean-Louis, DO, MPH

Latest:

Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Joe Scandura, MD, PhD

Latest:

Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Dickran G. Kazandjian, MD

Latest:

Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Vlad Gabriel Zaha, MD, PhD

Latest:

Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung Cancer

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Ira Braunschweig, MD

Latest:

Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

Ira Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.

M. Michele Blackwood, MD, FACS

Latest:

Dr Blackwood on the Significance of Early Breast Cancer Screenings

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Jennifer M. King, MD

Latest:

Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer

Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.

Samuel H. Cheshier, MD, PhD

Latest:

Expert Perspectives and Key Takeaways in pLGG Management

Experts discuss pediatric low-grade glioma (pLGG) as the most common childhood central nervous system (CNS) tumor, emphasizing a personalized, collaborative approach that integrates evolving molecular insights and patient factors to tailor treatments, improve quality of life, and offer hope through ongoing research and multidisciplinary care.

Michelle Shiller, DO

Michelle Shiller, DO, is a molecular genetic pathologist at Baylor University Medical Center

Latest:

Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP

Drs Kelly and Shiller discuss the importance of performing IHC testing for HER2 in NSCLC and recommendations for IHC testing implementation in practice.

University of Chicago Medicine

Latest:

UChicago Medicine Among the First to Offer Histotripsy for Liver Tumors

The University of Chicago Medicine treats patients with histotripsy, a technology that uses ultrasound energy to destroy liver tumors.

Amanda Cass, PharmD, BCPS, BCOP

Latest:

Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Ashwin Kishtagari, MD

Latest:

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis